Globus Medical, Inc. Class A Aktie News

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

The global AI market is projected to reach over $3 trillion by 2033, driven by growing investments from big tech, broader adoption, and booming data center requirements. Companies that provide AI software, hardware, and services are poised to exploit the megatrend and deliver significant profitable growth. AI stocks have outperformed over the past year, led by chipmakers, hyperscaler suppliers,...

Medical sector leader Globus Medical is in a buy zone from a cup-with-handle base that has a buy point of 92.48.

Globus Medical has provided preliminary fourth-quarter 2025 financial results. The company forecasts a more robust bottom line in 2026 than what analysts anticipate.

AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-report...

This medical products stock breaks out of a cup-with-handle base and is in a buy zone. The company makes technology used for spine surgery.

Globus Medical's spine business is a big earnings driver, propelling its stock closer to a buy point.

Globus Medical has rebounded strongly, driven by accelerating earnings and successful integration of acquisitions like NuVasive and Nevro. The company delivered on robust Q3 results, with 7% organic growth and a significant hike in full-year adjusted earnings guidance to $3.80 per share. Despite a 35% share price surge, shares trades at a reasonable 21x earnings, supported by a strong balance s...